Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Gilead Sciences, Inc. < Previous 1 2 3 4 5 6 7 8 9 Next > Veklury® (Remdesivir) Retains Antiviral Activity Against Omicron, Delta and Other Emergent SARS-CoV-2 Variants in Multiple In Vitro Studies February 11, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead to Present Latest Antiviral Research and Development Data at CROI 2022 Addressing Urgent Global Needs February 08, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Sciences to Present at Upcoming Investor Conferences February 03, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Sciences Announces 2.8 Percent Increase in First Quarter 2022 Dividend February 01, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Sciences Announces Fourth Quarter and Full Year 2021 Financial Results February 01, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD U.S. FDA Approves New Label Update for CAR T-Cell Therapy Yescarta® Showing Prophylactic Steriod Use Improves Management of Cytokine Release Syndrome January 31, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD FDA Approves Veklury® (Remdesivir) for the Treatment of Non-Hospitalized Patients at High Risk for COVID-19 Disease Progression January 21, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Sciences to Release Fourth Quarter & Full Year 2021 Financial Results on Tuesday, February 1, 2022 January 18, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Announces Clinical Trial Collaborations With Merck to Evaluate Trodelvy® in Combination With KEYTRUDA® in First-Line Metastatic Non-Small Cell Lung Cancer January 10, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Announces New England Journal of Medicine Publication of Data Demonstrating Veklury® (Remdesivir) Significantly Reduced Risk of Hospitalization in High-Risk Patients With COVID-19 December 22, 2021 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Announces Clinical Hold on Studies Evaluating Injectable Lenacapavir for HIV Treatment and Prevention Due to Vial Quality Concerns December 21, 2021 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Sciences to Present at Upcoming Investor Conference December 21, 2021 From Gilead Sciences, Inc. Via Business Wire Tickers GILD European Commission Expands Indication for Veklury (Remdesivir) for the Treatment of Adults Not on Supplemental Oxygen and Considered High Risk for COVID-19 Disease Progression December 21, 2021 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Daiichi Sankyo Authorizes the First YESCARTA® (Axicabtagene Ciloleucel) CAR T-cell Therapy Treatment Site in Japan December 16, 2021 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Yescarta® ZUMA-12 Study Demonstrates 78% Complete Response Rate as Part of First-Line Treatment in Newly Diagnosed High-Risk Large B-Cell Lymphoma December 13, 2021 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Yescarta® Demonstrates Durable Two-Year Clinical Benefit in Adults With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma Including Follicular Lymphoma December 11, 2021 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Yescarta® Is First CAR T-cell Therapy to Report Five-Year Survival Data From Pivotal Study Showing Durable Long-Term Survival in Patients With Refractory Large B-cell Lymphoma December 11, 2021 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Yescarta® CAR T-Cell Therapy Quadruples Median Event-Free Survival Duration Over Standard of Care in Second-Line Relapsed or Refractory Large B-Cell Lymphoma December 11, 2021 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Trodelvy® Demonstrates Clinical Benefit for Black Patients Consistent with Full Metastatic Triple-Negative Breast Cancer Population in ASCENT Study December 10, 2021 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead’s Bold Ambition of Transforming Triple-Negative Breast Cancer Treatment to Be Highlighted With New Data at SABCS November 29, 2021 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Trodelvy® (sacituzumab govitecan) Granted European Commission Marketing Authorization for Treatment of Metastatic Triple-Negative Breast Cancer in Second Line November 23, 2021 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Submits Biologics License Application to U.S. Food and Drug Administration for Bulevirtide, an Investigational Treatment for People Living With Chronic Hepatitis Delta November 19, 2021 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Sciences to Present at Upcoming Investor Conference November 18, 2021 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Exercises Options to Three Arcus Biosciences Clinical-Stage Programs and Adds Research Collaboration November 18, 2021 From Gilead Sciences, Inc. Via Business Wire Tickers GILD RCUS Everest Medicines and Gilead Sciences Jointly Announce Phase 2b Study of Sacituzumab Govitecan Conducted in China of Patients With Metastatic Triple-Negative Breast Cancer Meets Primary Overall Response Rate Endpoint November 10, 2021 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead to Present Data From Liver Disease Development Programs at The Liver Meeting® November 09, 2021 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead and Kite Oncology Demonstrate Broad Leadership in Cell Therapy and Expanding Blood Cancer Pipeline November 04, 2021 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Clinical and Patient-Reported Outcomes in People Living With HIV on Biktarvy® in Observational BICSTaR Study Demonstrate Consistent Efficacy Profile in Real-World Setting October 29, 2021 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Announces Clinical Trial Collaboration With Merck to Evaluate Trodelvy® (sacituzumab govitecan-hziy) in Combination With KEYTRUDA® (pembrolizumab) in Patients With First-Line Metastatic Triple-Negative Breast Cancer October 28, 2021 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Sciences Announces Third Quarter 2021 Financial Results October 28, 2021 From Gilead Sciences, Inc. Via Business Wire Tickers GILD < Previous 1 2 3 4 5 6 7 8 9 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.